The potential pathogenic role of glucocorticoid receptor polymorphisms in systemic lupus erythematosus and rheumatoid arthritis

Bazsó, Anna; Szappanos, Ágnes; Kövesdi, Annamária; Rásonyi, Rita; Nagy, Eszter; Patócs, Attila; Poór, Gyula; Kiss, Emese

doi:10.1016/j.autrev.2019.102362

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on anti-inflammatory and immunosuppressive ( 24 ) benefits of glucocorticoids (GCs), they are usually used to therapy RA. The subgroup analysis was performed by GCs use (present/absent) and indicated that VitD supplementation did not impact the treatment ( Figure 4 ).…”

Section: Resultsmentioning

confidence: 99%

The Role of Vitamin D in Combination Treatment for Patients With Rheumatoid Arthritis

Dong

et al. 2020

Front. Med.

View full text Add to dashboard Cite

Background: The aim of this study is to evaluate the clinical efficacy of vitamin D (VitD) supplementation in terms of response to treatment and improvement of disease activity in rheumatoid arthritis (RA). Methods: This study analyzed 1180 RA patients' records treated at Mianyang Central Hospital from February 2015 to July 2019. The patients were allocated into VitD group and control group based on their medical regimens. The outcome measures were primary efficacy, defined as treatment response-based EULAR response criteria in RA, and secondary efficacy, defined as improvement in disease activity indicators. Safety was evaluated according to the incidence of all-cause infections. Results: At month 6, the primary efficacy revealed that there were 22.8% good responders and 19.0% moderate responders in the VitD group, and 22.3% good responders and 22.3% moderate responders in the control group; there were no differences between the two groups (p = 0.754). The similar primary efficacy outcomes were observed at months 3, 12, and >12. The secondary efficacy indicated that there were no differences in most indexes between the two groups at months 1, 3, 6, 12, and >12. The subgroups (based on baseline DAS28 (CRP), glucocorticoids use and disease duration) analysis results suggested that VitD group didn't have the advantage for treating RA. The incidence of infections was similar in the two groups. Conclusion: VitD supplementation did not provide additional benefit for anti-rheumatic treatment. These data supported the need for prospective, randomized, controlled trials to evaluate the role of VitD supplementation in treating RA.

show abstract

Section: Resultsmentioning

confidence: 99%